How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: Brelovitug (BJT-778) (drug), Bulevirtide (drug)
How long the study runs: Study runs about 37 months (dates as stated)
About the drug or intervention: Brelovitug (BJT-778) — drug: Brelovitug (BJT-778), 300 mg administered subcutaneously once weekly for 96 weeks. · Bulevirtide — drug: Bulevirtide - once daily.
Patient visit burden: Not specified by the sponsor

Type of study: Testing a treatment
Ages: 18 Years and over
Who: All
Number of participants: 120
Started: 2026-02-26
Last checked: 2026-09

Plain English Summary

What is this study?

• Testing a new treatment for chronic hepatitis d
• Phase2/Phase3 - 120 participants
• This is a Phase 2b/3, randomized, open-label, multicenter trial evaluating the efficacy and safety of switching from bulevirtide to brelovitug for the treatment of chronic hepatitis Delta infection (CHD)

Who can take part?

• Ages 18 Years and over
• Diagnosed with chronic hepatitis d

Where?

• Cottingham - Castle Hill Hospital
• Cardiff - Cardiff and Vale University Health Board
• London - Barts Health NHS Trust
• London - King's College Hospital NHS Foundation Trust
• +2 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

This is a Phase 2b/3, randomized, open-label, multicenter trial evaluating the efficacy and safety of switching from bulevirtide to brelovitug for the treatment of chronic hepatitis Delta infection (CHD).

More detail

This is a Phase 2b/3, open-label, multicenter study evaluating the efficacy and safety of switching participants on bulevirtide to brelovitug for the treatment of chronic hepatitis delta (CHD).

Chronic Hepatitis D

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years and over
Who can join: All genders

What the study is looking for

✓Willing and able to provide written agreement to take part.
✓Male or female, ≥18 years of age at Screening.
✓Taking or willing to take TDF, TAF, or ETV at baseline, and willing to remain on stable treatment for the duration...
✓Currently taking bulevirtide treatment for CHD for ≥6 months at the time of Screening.
✓HDV RNA ≥100 IU/mL at Screening.

Who cannot take part

✗Evidence of decompensated liver disease (e.g., CTP Class B or C, history of liver encephalopathy, clinically...
✗Known history of immune-complex disease.
✗Active or clinically significant co-infection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV).
✗Evidence of other significant liver diseases (e.g., autoimmune hepatitis, primary biliary cholangitis, primary...
✗History of hepatocellular carcinoma (HCC) or evidence of HCC on screening imaging.

See the full criteria

Inclusion Criteria: 1. Willing and able to provide written informed consent. 2. Male or female, ≥18 years of age at Screening. 3. Taking or willing to take TDF, TAF, or ETV at baseline, and willing to remain on stable treatment for the duration of the study. 4. Currently taking bulevirtide treatment for CHD for ≥6 months at the time of Screening. 5. HDV RNA ≥100 IU/mL at Screening. Exclusion Criteria: 1. Evidence of decompensated liver disease (e.g., CTP Class B or C, history of hepatic encephalopathy, clinically significant ascites, or variceal bleeding). 2. Known history of immune-complex disease. 3. Active or clinically significant co-infection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV). 4. Evidence of other significant liver diseases (e.g., autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis). 5. History of hepatocellular carcinoma (HCC) or evidence of HCC on screening imaging.